Gilead Sciences, Inc. (GILD)

Listed in the US · Manufacturing · Biological products, (no diagnostic substances)

$165.61

As of 29 Oct 2026 close.

Facts from reported results and exchange filings. Not investment advice.

Share price

Prices load here as you scroll to them.

Last close $165.61 on 29 Oct 2026. The share price traded between $114.02 and $165.70 (intraday) over the last 12 months.

The closes as a table

DateClose

Key figures

1-year range (intraday)

Last close $165.61

Low $114.02High $165.70

Market cap$205.4Blast close × shares
Net profit−$3,863Mlast 12 months
Return on equity37.5%year to Dec 2025
EBITDA margin35.3%year to Dec 2025
Debt to equity1.10year to Dec 2025
Net margin28.9%year to Dec 2025
Dividend yield1.96%last 12 months

P/E isn't shown: the company made a loss over the last 12 months, and a loss has no P/E.

Price trend

Revenue and profit

RevenueNet profit$ million
010,00020,00030,000
YearDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue27,30527,28127,11628,75429,443
Net profit6,2254,5925,6654808,510
EBITDA margin37.5%28.1%29.4%7.1%35.3%
Borrowings26,69525,22924,98726,71024,937

$ million. Over three years, compounded: revenue grew 2.6% a year, net profit grew 22.8% a year.

Recent filings

Questions about Gilead Sciences, Inc.

What is Gilead Sciences, Inc.'s market value?

Gilead Sciences, Inc.'s market value is $205.4B as of 29 Oct 2026 close: the last close times the shares in issue.

Go further with GILD

Free to start: test a trading idea on GILD's real prices after costs, or open the full deep dive with ten years of numbers, red flags and management's record.

Same industry

The largest companies in the same industry (Biological products, (no diagnostic substances)), by market value.

Browse companies

The companies before and after this one, A to Z, and the lists it is in.

How these figures are worked out

The net profit for the last 12 months is the four latest reported quarters, so it can differ from the newest year's in the table below.